33278-96-5

Usage

Uses

Used in Chemical Synthesis:
2-(Bromomethyl)-2-methyl-1,3-dioxolane is used as a synthetic intermediate for the production of various organic compounds. Its unique structure allows it to be a versatile building block in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-(Bromomethyl)-2-methyl-1,3-dioxolane is used as a key intermediate in the development of new drugs. Its chemical properties enable it to be incorporated into drug molecules, potentially enhancing their efficacy and selectivity.
Used in Agrochemical Industry:
2-(Bromomethyl)-2-methyl-1,3-dioxolane is also utilized in the agrochemical industry for the synthesis of novel pesticides and other crop protection agents. Its unique structure can be exploited to create new molecules with improved biological activity and selectivity.
Used in Material Science:
In the field of material science, 2-(Bromomethyl)-2-methyl-1,3-dioxolane can be used as a component in the development of new polymers and materials with specific properties. Its chemical structure can contribute to the creation of materials with enhanced mechanical, thermal, or electrical properties.
Overall, 2-(Bromomethyl)-2-methyl-1,3-dioxolane is a versatile compound with a wide range of potential applications across various industries, including chemical synthesis, pharmaceuticals, agrochemicals, and material science. Its unique structure and properties make it a valuable building block for the development of new products and technologies.

InChI:InChI=1/C5H9BrO2/c1-5(4-6)7-2-3-8-5/h2-4H2,1H3

Upstream product

• 107-21-1 ethylene glycol 
• 598-31-2 1-bromoacetone 
• 2916-31-6 2,2-dimethyl-1,3-dioxolane 
• 67-64-1 acetone 

Downstream Products

• 222613-30-1 2-benzyl-4-(2-methyl-1,3-dioxolan-2-yl)butanal 
• 79708-89-7 4-benziloyloxy-1-(2-methyl-1,3-dioxolan-2-ylmethyl)piperidine 
• 79708-70-6 trans 4-benziloyloxy-1-(2-methyl-1,3-dioxolan-2-ylmethyl)-1-methylpiperidinium bromide 
• 79708-71-7 cis 4-benziloyloxy-1-(2-methyl-1,3-dioxolan-2-ylmethyl)-1-methylpiperidinium bromide 
• 1408078-71-6 C₂₆H₂₈O₄ 
• 1408078-69-2 tert-butyl(2-(1-methylvinyloxy)ethoxy)diphenylsilane 
• 1408078-57-8 2-[(1-methyl)vinyloxy]ethyl benzoate 
• 222613-34-5 1-<1-benzyl-3-(2-methyl-1,3-dioxolan-2-yl)propyl>hept-2-ynyl benzoate 
• 222613-33-4 1-<1-benzyl-3-(2-methyl-1,3-dioxolan-2-yl)propyl>prop-2-ynyl benzoate 
• 119014-14-1 1-benzoyl-5-hydroxymethyl-4-[methyl-(2-methyl-[1,3]dioxolan-2-ylmethyl)-amino]-1,2,2a,3,4,5-hexahydro-benz[cd]indol-5-ol 
• 124133-97-7 1-benzoyl-4-[methyl-(2-methyl-[1,3]dioxolan-2-ylmethyl)-amino]-2,2a,3,4-tetrahydro-1H-benz[cd]indol-5-one 
• 119640-77-6 1-benzoyl-4-[methyl-(2-methyl-[1,3]dioxolan-2-ylmethyl)-amino]-1,2,2a,3,4,5-hexahydro-benz[cd]indol-5-ol 

Relevant academic research and scientific papers

Optimization of Grignard ring-opening of α-brominated dioxolanes for the preparation of β-hydroxy-protected vinyl ethers by a three-step one-pot procedure

Aliphatic, cyclic, and aromatic benzoate-protected γ-hydroxy enol ethers were prepared from α-brominated dioxolanes by a three-step reaction procedure and a one-pot protocol involving Grignard reagent formation, ring-opening, and final benzoate protection

FURANOPYRIMIDINES

The present invention relates to furanopyrimidine compounds having the general Formula (I) and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula (I), methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula (I). The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula (I).

Catalytic Effect of Crown Ethers in the Bromination of 2-Alkyl-substituted 1,3-Dioxacyclanes

Bromination of 2-alkyl-1,3-dioxacyclanes with molecular bromine in the presence of crown ethers in benzene (chloroform) results, regardless of the acetal ring size, in exclusive formation of 2-(1-bromoalkyl)-1,3-dioxacyclanes in near-quantitative yields. The use of crown ethers allows the bromination to be accomplished at room temperature.

Bromination of 1,3-dioxolanes by molecular bromine

Bromination of alkyl-substituted 1,3-dioxolanes by molecular bromide in carbon tetrachloride occurs regioselectively with preservation of heterocycle and leads to formation of 2-(α-bromoalkyl)-1,3-dioxolane.

Dioxolane substituted 2,6-dinitroanilines

This invention discloses new chemical compounds of the formula STR1 wherein R1 is alkyl; R2 and R3 are hydrogen or alkyl; and X is selected from the group consisting of alkyl and haloalkyl, and their utility as herbicides.